◀ Back to MAPK3
MAPK3 — PRKCB
Pathways - manually collected, often from reviews:
-
KEGG Glutamatergic synapse:
PRKCA/PRKCB/PRKCG
→
MAPK1/MAPK3
(protein-compound, activation)
-
KEGG Leishmaniasis:
PRKCB
→
MAPK1/MAPK3
(protein-protein, activation)
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
PKC beta2 (PRKCB)
(modification, collaborate)
Takahashi et al., Oncogene 1999*, Xia et al., J Clin Invest 1996*
Evidence: mutant phenotype
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
PKC beta2 (PRKCB)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Takahashi et al., Oncogene 1999*, Xia et al., J Clin Invest 1996*
Evidence: mutant phenotype
Text-mined interactions from Literome
Trollér et al., FEBS Lett 2001
(Neuroblastoma) :
On the other hand,
PKCbeta inhibition
suppressed the TPA stimulated increase in neuropeptide Y mRNA, activation of neuropeptide Y gene promoter elements, and phosphorylation of
Erk1/2
Kapoor et al., J Lipid Res 2003
:
These findings identify for the first time a
role for
PKC beta in determining the specificity of
p42/44MAPK signaling by participating with pp90RSK in regulating gene expression
Guo et al., Cancer Sci 2008
(Carcinoma, Hepatocellular...) :
The phosphorylation of ERK ( 1/2 ) and p38
MAPK was
regulated by upregulated
protein kinase C beta (PKC beta) in HCC cells through the integrated use of PKC beta RNA interference, the PKC beta specific inhibitor enzastaurin and a PKC activator phorbol-12-myristate-13-acetate
Sauma et al., Cell Growth Differ 1996
(Colonic Neoplasms) :
Protein kinase C beta 1 and
protein kinase C beta 2
activate p57
mitogen activated protein kinase and block differentiation in colon carcinoma cells